Translated from our German original by AI. The German text was researched, written, and edited by the Psychedelia Foundation team and remains the authoritative version.
A book review in the Journal of Psychedelic Studies looks at the growing commercialization of the psychedelic renaissance. Its subject is Psychedelic Capitalism by the political scientists Jamie Brownlee and Kevin Walby, who critically examine how psychedelic substances are being turned into profit-driven commodities.
According to the authors, biotech companies, investors and venture capital firms developing psychedelic drugs are opening up a mass market potentially worth billions. They are especially critical of the emergence of a “psychedelic industrial complex”, the growing number of patents, and attempts to modify the substances’ chemical properties or duration of action for commercial ends. Rising demand in the Global North also has tangible consequences for Indigenous communities: separating the plants from their cultural and spiritual origins puts pressure on ecosystems and makes it harder for traditional communities to access their sacred medicines.
Brownlee and Walby do not deny that psychedelics have therapeutic potential for certain mental illnesses, but they stress that these substances are no cure-all for the global mental health crisis and cannot remove the social causes of psychological distress. As an alternative to monopolization by the medical and pharmaceutical system, they argue for community-controlled decriminalization. The reviewer, Sotillos, adds in closing that psychedelic capitalism is ultimately also an attempt to compensate for modern society’s crisis of meaning and spirituality through purely commercial offerings.